Form 4: Director Kabeer Aziz Acquires AN2 Therapeutics Shares

AN2 Therapeutics director Kabeer Aziz acquired 10,367 shares of common stock as non-cash compensation, increasing his direct beneficial ownership.

Summary

• Kabeer Aziz, a director of AN2 Therapeutics, Inc. (ANTX), acquired 10,367 shares of common stock.
• These shares were issued on October 10, 2025, in lieu of cash compensation under the company's non-employee director compensation policy.
• The acquired shares vested immediately upon issuance.
• Following this transaction, Mr. Aziz directly beneficially owns 40,919 shares of common stock.
• He also has indirect beneficial ownership of 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P., and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P., where he may be deemed to share voting and dispositive power.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, particularly as part of a compensation policy, is generally viewed positively as it aligns management's interests with shareholders. However, it is a routine transaction and not indicative of extraordinary news.

Positives

• A director, Kabeer Aziz, acquired 10,367 shares of common stock, indicating alignment of interests with shareholders.
• The shares were issued as non-cash compensation, which can conserve company cash.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Kabeer Aziz, as Secretary of Adjuvant Capital Management, L.L.C. (AC MGMT), may be deemed to share voting and dispositive power over shares held by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. Each person and entity disclaims beneficial ownership except to the extent of their pecuniary interest.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to direct share ownership.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of shares by a director as part of their compensation. While insider buying can be a positive signal, this specific transaction is not a discretionary open-market purchase and therefore does not provide a strong basis for a 'buy' or 'sell' recommendation. It primarily indicates alignment of interests.

Keywords

AN2 Therapeutics, ANTX, Kabeer Aziz, Form 4, insider trading, director compensation, stock acquisition, beneficial ownership